These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 16608533)

  • 1. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
    Han W; Han MR; Kang JJ; Bae JY; Lee JH; Bae YJ; Lee JE; Shin HJ; Hwang KT; Hwang SE; Kim SW; Noh DY
    BMC Cancer; 2006 Apr; 6():92. PubMed ID: 16608533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?
    Floiras JL; Hacene K; Turpin F; Spyratos F
    Int J Biol Markers; 2000; 15(2):135-8. PubMed ID: 10883886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
    Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
    Di Lauro L; Vici P; Del Medico P; Laudadio L; Tomao S; Giannarelli D; Pizzuti L; Sergi D; Barba M; Maugeri-Saccà M
    Breast Cancer Res Treat; 2013 Aug; 141(1):119-23. PubMed ID: 23982884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF-II mRNA expression in breast cancer: predictive value and relationship to other prognostic factors.
    Fiore E; Campani D; Muller I; Belardi V; Giustarini E; Rossi G; Pinchera A; Giani C
    Int J Biol Markers; 2010; 25(3):150-6. PubMed ID: 20677165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
    Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
    J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes.
    Loo LW; Grove DI; Williams EM; Neal CL; Cousens LA; Schubert EL; Holcomb IN; Massa HF; Glogovac J; Li CI; Malone KE; Daling JR; Delrow JJ; Trask BJ; Hsu L; Porter PL
    Cancer Res; 2004 Dec; 64(23):8541-9. PubMed ID: 15574760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
    Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
    J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
    Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
    J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Synchronous bilateral breast cancer in a male].
    García-Mejido JA; Delgado-Jiménez C; Gutiérrez-Palomino L; Sánchez-Sevilla M; Iglesias-Bravo E; Caballero-Fernández V
    Cir Cir; 2013; 81(3):225-7. PubMed ID: 23769252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid.
    Leboeuf R; Bénard F; Langlois MF
    Clin Nucl Med; 2006 Jul; 31(7):382-5. PubMed ID: 16785803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adjuvant treatment of operable breast cancer].
    Khosravi Shahi P; Izarzugaza Perón Y; Encinas García S; Díaz Muñoz de la Espada VM; Pérez Manga G
    An Med Interna; 2008 Jan; 25(1):36-40. PubMed ID: 18377195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
    Di Leo A; Buyse M
    J Clin Oncol; 2002 Apr; 20(7):1954-5. PubMed ID: 11919262
    [No Abstract]   [Full Text] [Related]  

  • 20. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.